There’s now 16 years’ price of established outcomes of various trials demonstrating the bortezomib efficiency in treating multiple myeloma. Over this time around, the development of bortezomib is a major break through in treating multiple myeloma. Bortezomib could be administered within the outpatient setting with manageable toxicities. Areas covered: A literature search was transported out using PubMed and Google Scholar. This review gives an introduction to the critical role from the bortezomib in multiple myeloma and offers an extensive review of key clinical benefit and safety data using the bortezomib. Initial toxicity profile has improved dramatically with introduction of subcutaneous administration as well as, implementation of guidelines for early recognition and treatment. Triplet and quadruplets of bortezomib with agents possessing similar toxicities constitute challenging. Expert opinion: Bortezomib is an integral part of current anti-myeloma therapy with a decent clinical effectiveness and manageable negative effects. Although gastrointestinal disturbances and fatigue are the most typical negative effects, peripheral neuropathy and thrombocytopenia would be the key dose-restricting toxicities of bortezomib-based combination regimens. As these combinations are better, with faster disappearance of disease related signs and symptoms and anti-inflammatory results of bortezomib toxicities weren’t discovered to be augmented.